Condition: Ovarian Cancer · Sponsor: ARCAGY/ GINECO GROUP
Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.
This description comes directly from the study's public registry record.
Sidonie Adam · (0033) 1 84 85 20 18 · sadam@arcagy.org
Always discuss trial participation with your own doctor first.
| ICO Paul Papin | Angers, France | Not Yet Recruiting |
| Sainte Catherine Institut du cancer Avignon-Provence | Avignon, France | Not Yet Recruiting |
| CHRU Besançon - Hôpital Jean Minjoz | Besançon, France | Not Yet Recruiting |
| Clinique Tivoli-Ducos | Bordeaux, France | Not Yet Recruiting |
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Hôpital Morvan CHRU de Brest | Brest, France | Not Yet Recruiting |
| HCL - Groupe Hospitalier Est | Bron, France | Not Yet Recruiting |
| Centre François Baclesse | Caen, France | Recruiting |
| Centre Hospitalier de Cholet | Cholet, France | Not Yet Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Not Yet Recruiting |
| CHU de Dijon - Bourgogne | Dijon, France | Not Yet Recruiting |
| Centre Georges François Leclerc | Dijon, France | Not Yet Recruiting |
+ 76 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05183984